Search clinical trials for: CC-10004

Total 1474 results

University of Cincinnati
Medical University of South Carolina; Celgene Corporation

Completed

The Efficacy and Safety of CC-10004 in Chronic Cutaneous Sarcoidosis

Sarcoidosis | Cutaneous Sarcoidosis

United States
Celgene

Completed

2-part Study to Assess Safety, Pharmacokinetics & Pharmacodynamics of CC-220 & Effect of Food on CC-220 in Healthy Subjects

Healthy

United States
OSI Pharmaceuticals
Canadian Cancer Trials Group

Completed

OSI-774 (Tarceva) Plus Gemcitabine in Patients With Locally Advanced, Unresectable or Metastatic Pancreatic Cancer.

Pancreatic Cancer

United States, Canada, Australia, Israel, Singapore, United Kingdom, Germany, Belgium, Romania, Poland, Argentina, Brazil, Chile, Greece, Italy, Mexico, New Zealand
Radboud University Medical Center
Norgine

Unknown

Comparison of AMR and ADR Between Endocuff Vision-assisted and Conventional Colonoscopy: a Multicenter Randomized Trial (EXCEED)

Colorectal Neoplasms

Netherlands, Greece
Juno Therapeutics, Inc., a Bristol-Myers Squibb...

Recruiting

A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of BMS-986393 in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma

United States
Bristol-Myers Squibb

Withdrawn

A Study of Absorption, Metabolism, and Elimination CC-90010 in Participants With Advanced Solid Tumors

Advanced Solid Tumors

Spain
Celgene

Withdrawn

A Phase 2 Study With CC-220 in Skin Sarcoidosis

Sarcoidosis
Celgene

Recruiting

Study of CC-96191 in Participants With Relapsed or Refractory Acute Myeloid Leukemia

Leukemia, Myeloid

United States, France, Canada
Celgene

Active, not recruiting

Study to Evaluate the Safety and Tolerability of CC-92328 in Participants With Relapsed and/or Refractory Multiple Myeloma

Multiple Myeloma

Spain, Canada, United States
Celgene

Completed

Study to Evaluate the Safety, Tolerability, Pharmacokinetic and Pharmacodynamic of CC-95775 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin Lymphoma

Lymphoma, Non-Hodgkin

France, Spain
Celgene

Completed

Study to Evaluate the Pharmacokinetic Comparability of CC-93538 From Two Different Drug Concentrations in Healthy Adult Subjects

Healthy Volunteers

United States
Celgene

Completed

Japanese Pharmacokinetic Bridging Study for CC-93538

Healthy Volunteers

United States
Celgene

Completed

A Study of Safety, Tolerability, and Pharmacokinetics of Multiple-Dose CC-90001 in Japanese and Caucasian Healthy Subjects

Healthy Volunteer

United States
Celgene

Completed

Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Food Effect of Single Ascending Doses of CC-92480 in Healthy Subjects

Healthy Volunteer

United States
Celgene

Terminated

A Phase I, Open-Label, Dose-Escalation Study of CC-11006 In Subjects With Low- or Intermediate-1 Risk Myelodysplastic Syndromes

Myelodysplastic Syndrome

United States
Celgene

Completed

Study to Evaluate Pharmacokinetics of Single Oral Doses of Formulated and Non-Formulated CC-122, and Food Effect Study

Clinical Pharmacology, Healthy Male Volunteer Study

United States
Shenzhen Geno-Immune Medical Institute

Unknown

Engineered Immune Effectors Against Cervical Cancer

Cervical Cancer

China
Universitair Ziekenhuis Brussel

Unknown

Single-center Prospective Cumulus Cell Test Study in rFSH Patients

Infertility

Belgium
Universitair Ziekenhuis Brussel

Unknown

Single-center Prospective Cumulus Cell Test Study (CC-Test)

Pregnancy

Belgium
Celgene

Completed

Safety and PK Study of CC-90001 in Subjects With Pulmonary Fibrosis

Pulmonary Fibrosis

United States, Australia
National Cancer Institute (NCI)

Completed

CC-8490 in Treating Patients With Recurrent or Refractory High-Grade Gliomas

Brain and Central Nervous System Tumors

United States
Boston Medical Center

Completed

Chemotherapy in Treating Patients With Chronic Lymphocytic Leukemia

Leukemia

United States
Celgene Corporation

Completed

Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade Gliomas

Glioblastoma | Malignant Gliomas

United States
Celgene

Active, not recruiting

CNS Penetration, PK and PD of Preoperative CC-90010 in Progressive/Recurrent Diffuse Astrocytoma, Anaplastic Astrocytoma and Glioblastoma

Glioblastoma | Astrocytoma

United States, Spain
Celgene

Active, not recruiting

A Dose Finding Study of CC-96673 in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin

France, Canada, United States, Spain
Bristol-Myers Squibb

Completed

A Study to Evaluate the Drug Levels of [14C]CC-99677 in Healthy Male Participants

Healthy Volunteers

United States
Jean Edward

Completed

Coverage and Cost-of-Care (CC) Links- Financial Navigation Program (CC Links)

Financial Stress | Survivorship | Hematologic Cancer

United States
Benjamin Rose Institute on Aging

Withdrawn

SHARE for Persons With Chronic Conditions and Their Family Caregivers (SHARE-CC)

Family Caregivers | Chronic Health Conditions

United States
Celgene

Completed

Evaluate the Pharmacokinetics of CC-220 in Subjects With Mild, Moderate, or Severe Hepatic Impairment Compared With Healthy Subjects

Healthy Volunteers | Hepatic Impairment

United States
Celgene

Terminated

Safety and PK Study of CC-90003 in Relapsed/Refractory Solid Tumors

Neoplasm Metastasis

United States, Australia
Celgene

Completed

Study to Determine the Safety and Preliminary Efficacy of CC-1088 in the Treatment of Myelodysplastic Syndromes

Myelodysplastic Syndrome

United States
Sun Yat-sen University
Ministry of Health, China; Xidian University

Completed

Validation of the Utility of Rare Disease Intelligence Platform

Cataract | Artificial Intelligence

China
Amgen

Completed

A Phase 4 Study of Efficacy and Safety of Apremilast in Subjects With Moderate Plaque Psoriasis. (UNVEIL)

Parapsoriasis

United States
Kaiser Clinic and Hospital

Completed

Optimization and Follow-up of the Consecutive Use of Two Intragastric Balloons in the Treatment of Obesity

Obesity | Metabolic Syndrome

Brazil
EarliTec Diagnostics, Inc
Marcus Autism Center

Recruiting

Dynamic Quantification of Social-Visual Engagement in Autism Spectrum Disorder (ASD) For Children Ages 31-84 Months (MEASURE-ASD2)

Autism Spectrum Disorder | Autism

United States
University of Alberta

Withdrawn

Does Higher (100% Oxygen) Versus Lower (21% Oxygen) During CC+SI During CPR of Asphyxiated Newborns Improve Time to ROSC (SURV1VE-O2)

Bradycardia Neonatal | Birth Asphyxia | Heart; Arrest, Newborn

Canada
Celgene

Active, not recruiting

A Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CC-90010 in Subjects With Advanced Solid Tumors and Relapsed/Refractory Non-Hodgkin's Lymphomas

Neoplasms | Lymphoma, Non-Hodgkin

France, Italy, Japan, Spain
Celgene

Active, not recruiting

A Dose-finding Study of CC-90009 in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Relapsed or Refractory Higher-risk Myelodysplastic Syndromes

Myelodysplastic Syndromes | Leukemia, Myeloid, Acute

France, United States, Canada, Norway, Spain, United Kingdom
Celgene

Completed

A Study of CC-122 to Assess the Safety and Tolerability in Japanese Patients With Advanced Solid Tumors and Non-Hodgkin's Lymphoma (NHL)

Lymphoma, Non-Hodgkin

Japan
Nobel Biocare

Completed

A 5-year Clinical Evaluation Study on NobelReplace Conical Connection Implants

Healthy | Implant
Celgene

Completed

A Study to Assess the Pharmacokinetics of CC-90001 in Subjects With Mild, Moderate, and Severe Hepatic Impairment Compared With Healthy Subjects

Hepatic Impairment

United States
Celgene

Completed

Radiolabeled Study of CC-122 in Healthy Subjects

Healthy Volunteers

United States
Universitair Ziekenhuis Brussel

Unknown

Multicenter Prospective Cumulus Cell Test Study (MC_CC-Test)

Pregnancy

Belgium
Celgene

Completed

A Study to Assess the Pharmacokinetics of CC-122 in Subjects With Mild, Moderate, and Severe Renal Impairment

Renal Insufficiency

United States
Celgene

Completed

A Study to Assess the Relative Bioavailability of a New CC-220 Capsule Formulation, Compared to a Reference CC-220 Capsule Formulation, in Healthy Adult Subjects

Healthy Volunteers

United States
Celgene Corporation

Completed

Effect of UV Exposure on the PD of Multiple Doses of CC-90001 and Pilot Food Effect Study

Healthy Subjects

United States
Celgene Corporation

Terminated

Study to Determine the Optimal Biologic Dose of CC-401 in Subjects With High-Risk Myeloid Leukemia

Myeloid Leukemia

United States
Celgene

Completed

A Study to Evaluate the Efficacy and Safety of CC-220 in Subjects With Active Systemic Lupus Erythematosus

Lupus Erythematosus, Systemic

United States, Belgium, Germany, Spain, Canada, Serbia, Colombia, Poland, Argentina, Brazil, Mexico, Hungary, France, Russian Federation, Italy
Celgene

Completed

A Study to Assess Safety, Tolerability, and Pharmacokinetics of CC-92480 Formulations in Healthy Adult Participants

Healthy Volunteers

United States
Celgene

Terminated

A Safety Study of CC-92252 in Healthy Adult Subjects and Adult Subjects With Psoriasis

Psoriasis | Healthy Volunteers

Germany

3

Subscribe